Purpose of Review: Following significant advancements in cancer therapeutics and survival, the risk of cancer therapy-related cardiotoxicity (CTRC) is increasingly recognized. With ongoing efforts to reduce cardiovascular morbidity and mortality in cancer patients and survivors, cardiac biomarkers have been studied for both risk stratification and monitoring during and after therapy to detect subclinical disease. This article will review the utility for biomarker use throughout the cancer care continuum. Recent Findings: A recent meta-analysis shows utility for troponin in monitoring patients at risk for CTRC during cancer therapy. The role for natriuretic peptides is less clear but may be useful in patients receiving proteasome inhibitors. Early studies explore use of myeloperoxidase, growth differentiation factor 15, galectin 3, micro-RNA, and others as novel biomarkers in CTRC. Summary: Biomarkers have potential to identify subclinical CTRC and may reveal opportunities for early intervention. Further research is needed to elucidate optimal biomarkers and surveillance strategies.

Original languageEnglish
Pages (from-to)133-146
Number of pages14
JournalCurrent Cardiology Reports
Issue number3
StatePublished - Mar 2023


  • Biomarkers
  • Cancer therapy
  • Cardio-oncology
  • Cardiotoxicity
  • Risk prediction
  • Screening


Dive into the research topics of 'Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology'. Together they form a unique fingerprint.

Cite this